arrow
A

Alessandro Gozzetti

University of Siena
H指数:41
被引数:6,808

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Taginostat, a new quinolone-based HDAC6 inhibitor, promotes apoptosis of chronic lymphocytic leukemia cells in vitro and in vivo by activating STAT4

塔吉诺stat,一种新型喹诺酮类HDAC6抑制剂,通过激活STAT4在体外和体内促进慢性淋巴细胞白血病细胞的凋亡

2026-07-040
PRE
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma

林伏塞尔塔马布与真实世界国际骨髓瘤工作组三药类暴露的复发/难治性多发性骨髓瘤标准护理的比较

2026-03-250
OAAI
Left Atrial Strain Correlation with Functional Capacity and Additional Prognostic Value of Speckle Tracking in Cardiac Amyloidosis: A Prospective, Single-Center Study

心脏淀粉样变性中左房应变与功能能力的相关性和斑点追踪的额外预后价值: 一项前瞻性单中心研究

2026-02-080
OAAI
Rethinking the feasibility and safety of venetoclax-obinutuzumab in chronic lymphocytic leukemia: nontraditional factors may play a role in clinical practice

重新思考维奈克拉-奥滨尤妥珠单抗在慢性淋巴细胞白血病中的可行性与安全性:非传统因素可能在临床实践中发挥作用

2026-01-014
OA
Real-life efficacy and safety of vemurafenib plus rituximab in relapsed or refractory hairy-cell leukemia: A multicenter Italian retrospective study (HCL-PG03R)

vemurafenib联合利妥昔单抗治疗复发或难治性毛细胞白血病的真实世界疗效与安全性:一项多中心意大利回顾性研究(HCL-PG03R)

2025-11-140
OAAI
Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomes

慢性淋巴细胞白血病患者接受伊布替尼治疗的弥漫性大b细胞淋巴瘤的Richter转化: 危险因素和结果

Leukemia
IF13.4
2025-06-250
OAAI
Apoliprotein E-mediated ferroptosis controls cellular proliferation in chronic lymphocytic leukemia
LEUKEMIA
IF13.4
2024-10-230
OAAI
Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL

慢性淋巴细胞白血病患者的治疗策略和治疗顺序: 欧洲CLL研究计划ERIC的国际研究

2024-09-170
OAAI
Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms
LEUKEMIA
IF13.4
2024-06-084
OAAI
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials
2024-05-314
PRE
A novel potent class I HDAC inhibitor reverses the STAT4/p66Shc apoptotic defect in B cells from chronic lymphocytic leukemia patients
2024-05-012
OAAI
Leukemic cell-secreted interleukin-9 suppresses cytotoxic T cell-mediated killing in chronic lymphocytic leukemia
2024-02-155
OAAI
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

CLL历史上的其他恶性肿瘤: ERIC进行的一项国际多中心研究,欧洲CLL研究倡议,和谐

2023-11-016
OAAI
Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study

患者对慢性淋巴细胞白血病治疗的偏好: 选择研究

2023-09-296
OA
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials
2023-07-1312
OAAI